|
|
|
Volumn 8, Issue 4, 1995, Pages 579-586
|
|
High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma
a
|
|
Author keywords
Asthma; Bone marker; Budesonide; Double blind; Fluticasone propionate; Lung function
|
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
BIOLOGICAL MARKER;
BUDESONIDE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
CORTICOSTEROID;
FLUTICASONE PROPIONATE;
METHYLXANTHINE;
ADULT;
ARTICLE;
ASTHMA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
HEADACHE;
HUMAN;
LUNG FUNCTION;
MAJOR CLINICAL STUDY;
MALE;
PEAK EXPIRATORY FLOW;
PRIORITY JOURNAL;
SIDE EFFECT;
SPIROMETRY;
AEROSOLS;
ALBUTEROL;
ANDROSTADIENES;
ANTI-INFLAMMATORY AGENTS;
ASTHMA;
BUDESONIDE;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
NEBULIZERS AND VAPORIZERS;
PEAK EXPIRATORY FLOW RATE;
PREGNENEDIONES;
RESPIRATORY FUNCTION TESTS;
TIME FACTORS;
|
|
EID: 0029075287
PISSN: 09031936
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (159)
|
|
References (0)
|
